748 related articles for article (PubMed ID: 33548227)
1. How glycobiology can help us treat and beat the COVID-19 pandemic.
Lardone RD; Garay YC; Parodi P; de la Fuente S; Angeloni G; Bravo EO; Schmider AK; Irazoqui FJ
J Biol Chem; 2021; 296():100375. PubMed ID: 33548227
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities.
Delcuve GP; Lakowski TM; Su RC; Beacon TH; Davie JR
IUBMB Life; 2020 Nov; 72(11):2313-2330. PubMed ID: 32918855
[TBL] [Abstract][Full Text] [Related]
3. Plant lectins as prospective antiviral biomolecules in the search for COVID-19 eradication strategies.
Ahmed MN; Jahan R; Nissapatorn V; Wilairatana P; Rahmatullah M
Biomed Pharmacother; 2022 Feb; 146():112507. PubMed ID: 34891122
[TBL] [Abstract][Full Text] [Related]
4. The promise of glycomics, glycan arrays and carbohydrate-based vaccines.
Lepenies B; Seeberger PH
Immunopharmacol Immunotoxicol; 2010 Jun; 32(2):196-207. PubMed ID: 20141495
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 Proteins: Are They Useful as Targets for COVID-19 Drugs and Vaccines?
Mohammed MEA
Curr Mol Med; 2022; 22(1):50-66. PubMed ID: 33622224
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 Evolutionary Adaptation toward Host Entry and Recognition of Receptor O-Acetyl Sialylation in Virus-Host Interaction.
Kim CH
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32604730
[TBL] [Abstract][Full Text] [Related]
7. Status of mannose-binding lectin (MBL) and complement system in COVID-19 patients and therapeutic applications of antiviral plant MBLs.
Gupta A; Gupta GS
Mol Cell Biochem; 2021 Aug; 476(8):2917-2942. PubMed ID: 33745077
[TBL] [Abstract][Full Text] [Related]
8. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
9. Broad-spectrum prodrugs with anti-SARS-CoV-2 activities: Strategies, benefits, and challenges.
Wang Z; Yang L
J Med Virol; 2022 Apr; 94(4):1373-1390. PubMed ID: 34897729
[TBL] [Abstract][Full Text] [Related]
10. Modulating the host immune response to fight against COVID-19: Where are we in 2021?
Hertanto DM; Sutanto H; Wiratama BS; Wungu CDK
Virulence; 2021 Dec; 12(1):1732-1736. PubMed ID: 34224330
[No Abstract] [Full Text] [Related]
11. RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery.
Zhu W; Chen CZ; Gorshkov K; Xu M; Lo DC; Zheng W
SLAS Discov; 2020 Dec; 25(10):1141-1151. PubMed ID: 32660307
[TBL] [Abstract][Full Text] [Related]
12. Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants.
Fenizia C; Galbiati S; Vanetti C; Vago R; Clerici M; Tacchetti C; Daniele T
Microbiol Spectr; 2022 Feb; 10(1):e0150421. PubMed ID: 34985303
[TBL] [Abstract][Full Text] [Related]
13. Structural biology of SARS-CoV-2: open the door for novel therapies.
Yan W; Zheng Y; Zeng X; He B; Cheng W
Signal Transduct Target Ther; 2022 Jan; 7(1):26. PubMed ID: 35087058
[TBL] [Abstract][Full Text] [Related]
14. Growth Factor Receptor Signaling Inhibition Prevents SARS-CoV-2 Replication.
Klann K; Bojkova D; Tascher G; Ciesek S; Münch C; Cinatl J
Mol Cell; 2020 Oct; 80(1):164-174.e4. PubMed ID: 32877642
[TBL] [Abstract][Full Text] [Related]
15. COVID-19 Drug Development.
Kim S
J Microbiol Biotechnol; 2022 Jan; 32(1):1-5. PubMed ID: 34866128
[TBL] [Abstract][Full Text] [Related]
16. Drug Discovery of Small Molecules for the Treatment of COVID-19: A Review on Clinical Studies.
Goel B; Bhardwaj N; Tripathi N; Jain SK
Mini Rev Med Chem; 2021; 21(12):1431-1456. PubMed ID: 33371848
[TBL] [Abstract][Full Text] [Related]
17. Bitter-sweet symphony: glycan-lectin interactions in virus biology.
Van Breedam W; Pöhlmann S; Favoreel HW; de Groot RJ; Nauwynck HJ
FEMS Microbiol Rev; 2014 Jul; 38(4):598-632. PubMed ID: 24188132
[TBL] [Abstract][Full Text] [Related]
18. Current approaches for target-specific drug discovery using natural compounds against SARS-CoV-2 infection.
Khare P; Sahu U; Pandey SC; Samant M
Virus Res; 2020 Dec; 290():198169. PubMed ID: 32979476
[TBL] [Abstract][Full Text] [Related]
19. Emergence and molecular mechanisms of SARS-CoV-2 and HIV to target host cells and potential therapeutics.
Saleemi MA; Ahmad B; Benchoula K; Vohra MS; Mea HJ; Chong PP; Palanisamy NK; Wong EH
Infect Genet Evol; 2020 Nov; 85():104583. PubMed ID: 33035643
[TBL] [Abstract][Full Text] [Related]
20. Nanomedicine for the SARS-CoV-2: State-of-the-Art and Future Prospects.
Varahachalam SP; Lahooti B; Chamaneh M; Bagchi S; Chhibber T; Morris K; Bolanos JF; Kim NY; Kaushik A
Int J Nanomedicine; 2021; 16():539-560. PubMed ID: 33519200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
